These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28852801)

  • 21. 21st century drug development: advances, opportunities and challenges.
    Bhogal N
    Altern Lab Anim; 2009 Sep; 37(4):335-9. PubMed ID: 19807207
    [No Abstract]   [Full Text] [Related]  

  • 22. Current drug metabolism.
    Kerns EH
    Curr Drug Metab; 2008 Nov; 9(9):845-6. PubMed ID: 18991579
    [No Abstract]   [Full Text] [Related]  

  • 23. Acute toxicity and long-term safety evaluation of the crude extract from rhizomes of Limonium brasiliense in mice and rats.
    Antonelli-Ushirobira TM; Blainski A; Fernandes HG; Moura-Costa GF; Costa MA; Campos-Shimada LB; Salgueiro-Pagadigorria CL; Kaneshima EN; Becker TC; Leite-Mello EV; Mello JC
    J Ethnopharmacol; 2015 Nov; 174():293-8. PubMed ID: 26297844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perspective of humanized mouse models for assessing PK/PD and toxic profile of drug candidates in preclinical study.
    Chiba K
    Drug Metab Pharmacokinet; 2014; 29(1):1-2. PubMed ID: 24573168
    [No Abstract]   [Full Text] [Related]  

  • 25. Adverse Drug Reactions: Type A (Intrinsic) or Type B (Idiosyncratic).
    Iasella CJ; Johnson HJ; Dunn MA
    Clin Liver Dis; 2017 Feb; 21(1):73-87. PubMed ID: 27842776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Progress report. Possibilities and limitations of the in vitro technic for prenatal toxicologic studies].
    Bleyl DW
    Nahrung; 1984; 28(10):1053-63. PubMed ID: 6513999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ex Vivo Metrics, a preclinical tool in new drug development.
    Curtis CG; Bilyard K; Stephenson H
    J Transl Med; 2008 Jan; 6():5. PubMed ID: 18215298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rapid pharmacokinetics screening of drug candidates in vitro and in vivo].
    Dong XN; Zhu XX; Meng ZY; Liu JL; Cao YL; Dou GF
    Yao Xue Xue Bao; 2009 Nov; 44(11):1309-12. PubMed ID: 21355332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reasons for monitoring kinetics in safety evaluation studies.
    Hawkins DR; Chasseaud LF
    Arch Toxicol Suppl; 1985; 8():165-72. PubMed ID: 3868346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zebrafish based assays for the assessment of cardiac, visual and gut function--potential safety screens for early drug discovery.
    Berghmans S; Butler P; Goldsmith P; Waldron G; Gardner I; Golder Z; Richards FM; Kimber G; Roach A; Alderton W; Fleming A
    J Pharmacol Toxicol Methods; 2008; 58(1):59-68. PubMed ID: 18585469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical assessment of β-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug.
    Fattahi MJ; Abdollahi M; Agha Mohammadi A; Rastkari N; Khorasani R; Ahmadi H; Tofighi Zavareh F; Sedaghat R; Tabrizian N; Mirshafiey A
    Immunopharmacol Immunotoxicol; 2015; 37(6):535-40. PubMed ID: 26584020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and toxicokinetics of bio-pharmaceuticals: technical problems.
    Kawai M
    J Toxicol Sci; 1996 Dec; 21(5):535-7. PubMed ID: 9035067
    [No Abstract]   [Full Text] [Related]  

  • 34. Investigating cell type specific mechanisms contributing to acute oral toxicity.
    Prieto P; Graepel R; Gerloff K; Lamon L; Sachana M; Pistollato F; Gribaldo L; Bal-Price A; Worth A
    ALTEX; 2019; 36(1):39-64. PubMed ID: 30015985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Organs-on-a-chip: Current applications and consideration points for in vitro ADME-Tox studies.
    Ishida S
    Drug Metab Pharmacokinet; 2018 Feb; 33(1):49-54. PubMed ID: 29398302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicological evaluation of ferrous N-carbamylglycinate chelate: Acute, Sub-acute toxicity and mutagenicity.
    Wan D; Zhou X; Xie C; Shu X; Wu X; Yin Y
    Regul Toxicol Pharmacol; 2015 Nov; 73(2):644-51. PubMed ID: 26364753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A human liver microphysiology platform for investigating physiology, drug safety, and disease models.
    Vernetti LA; Senutovitch N; Boltz R; DeBiasio R; Shun TY; Gough A; Taylor DL
    Exp Biol Med (Maywood); 2016 Jan; 241(1):101-14. PubMed ID: 26202373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs and the liver.
    Reidenberg MM; Breckenridge A
    Clin Pharmacol Ther; 1998 Oct; 64(4):353-4. PubMed ID: 9797790
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs.
    Regenthal R; Krueger M; Koeppel C; Preiss R
    J Clin Monit Comput; 1999 Dec; 15(7-8):529-44. PubMed ID: 12578052
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety evaluation to support First-In-Man investigations II: toxicology studies.
    Baldrick P
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):237-43. PubMed ID: 18501490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.